Current Liabilities
Accrued Expenses
Royalty Pharma Accrued Expenses decreased by 67.1% to $17.48M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.0%, from $18.6M to $17.48M. Over 3 years (FY 2022 to FY 2025), Accrued Expenses shows an upward trend with a 62.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2022
Last reportedQ1 2026May 6, 2026
Metric ID:
accrued_expensesHistorical Data
13 periods
| Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.4M | $0 | $0 | $11.38M | $9.02M | $97.49M | $31.2M | $68.6M | $18.6M | $3.08M | $3.12M | $53.16M | $17.48M |
| QoQ Change | — | -100.0% | — | — | -20.7% | +981.0% | -68.0% | +119.9% | -72.9% | -83.5% | +1.5% | >999% | -67.1% |
| YoY Change | — | — | — | -8.3% | — | — | — | +503.1% | +106.2% | -96.8% | -90.0% | -22.5% | -6.0% |
Range$0 – $97.49M
CAGR+12.1%
Avg YoY Growth+55.1%
Median YoY Growth-8.3%
Accrued Expenses at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's accrued expenses?
- Royalty Pharma (RPRX) reported accrued expenses of $17.48M in Q1 2026.
- How has Royalty Pharma's accrued expenses changed year-over-year?
- Royalty Pharma's accrued expenses decreased by 6.0% year-over-year, from $18.6M to $17.48M.
- What is the long-term trend for Royalty Pharma's accrued expenses?
- Over 3 years (2022 to 2025), Royalty Pharma's accrued expenses has grown at a 62.5% compound annual growth rate (CAGR), from $12.4M to $53.16M.